| Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine M Levine-Tiefenbrun, I Yelin, R Katz, E Herzel, Z Golan, L Schreiber, ... Nature medicine 27 (5), 790-792, 2021 | 491 | 2021 |
| Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine B Mizrahi, R Lotan, N Kalkstein, A Peretz, G Perez, A Ben-Tov, G Chodick, ... Nature communications 12 (1), 6379, 2021 | 288 | 2021 |
| Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2 M Levine-Tiefenbrun, I Yelin, H Alapi, R Katz, E Herzel, J Kuint, G Chodick, ... Nature medicine 27 (12), 2108-2110, 2021 | 233 | 2021 |
| Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections S Gazit, R Shlezinger, G Perez, R Lotan, A Peretz, A Ben-Tov, D Cohen, ... MedRxiv, 2021 | 208 | 2021 |
| The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data G Chodick, L Tene, RS Rotem, T Patalon, S Gazit, A Ben-Tov, C Weil, ... Clinical Infectious Diseases 74 (3), 472-478, 2022 | 199 | 2022 |
| Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine T Patalon, S Gazit, VE Pitzer, O Prunas, JL Warren, DM Weinberger JAMA Internal Medicine 182 (2), 179-184, 2022 | 145 | 2022 |
| Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel O Prunas, JL Warren, FW Crawford, S Gazit, T Patalon, DM Weinberger, ... Science 375 (6585), 1151-1154, 2022 | 140 | 2022 |
| Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine T Patalon, Y Saciuk, A Peretz, G Perez, Y Lurie, Y Maor, S Gazit Nature Communications 13 (1), 3203, 2022 | 125 | 2022 |
| Multi-institutional validation of a mammography-based breast cancer risk model A Yala, PG Mikhael, F Strand, G Lin, S Satuluru, T Kim, I Banerjee, ... Journal of Clinical Oncology 40 (16), 1732, 2022 | 110 | 2022 |
| Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization G Chodick, L Tene, T Patalon, S Gazit, AB Tov, D Cohen, K Muhsen JAMA network open 4 (6), e2115985-e2115985, 2021 | 102 | 2021 |
| The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence G Chodick, L Tene, T Patalon, S Gazit, AB Tov, D Cohen, K Muhsen Medrxiv, 2021.01. 27.21250612, 2021 | 100 | 2021 |
| Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals O Milman, I Yelin, N Aharony, R Katz, E Herzel, A Ben-Tov, J Kuint, ... Nature medicine 27 (8), 1367-1369, 2021 | 97 | 2021 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naturally acquired immunity versus vaccine-induced immunity, reinfections versus breakthrough infections: a … S Gazit, R Shlezinger, G Perez, R Lotan, A Peretz, A Ben-Tov, E Herzel, ... Clinical Infectious Diseases 75 (1), e545-e551, 2022 | 83 | 2022 |
| Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control … S Gazit, Y Saciuk, G Perez, A Peretz, VE Pitzer, T Patalon Bmj 377, 2022 | 80 | 2022 |
| Decreased SARS-CoV-2 viral load following vaccination M Levine-Tiefenbrun, I Yelin, R Katz, E Herzel, Z Golan, L Schreiber, ... MedRxiv, 2021.02. 06.21251283, 2021 | 79 | 2021 |
| Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities I Yelin, R Katz, E Herzel, T Berman-Zilberstein, A Ben-Tov, J Kuint, S Gazit, ... medrxiv, 2021.03. 16.21253686, 2021 | 75 | 2021 |
| The incidence of SARS-CoV-2 reinfection in persons with naturally acquired immunity with and without subsequent receipt of a single dose of BNT162b2 vaccine: a retrospective … S Gazit, R Shlezinger, G Perez, R Lotan, A Peretz, A Ben-Tov, E Herzel, ... Annals of Internal Medicine 175 (5), 674-681, 2022 | 61 | 2022 |
| Waning of SARS-CoV-2 booster viral-load reduction effectiveness M Levine-Tiefenbrun, I Yelin, H Alapi, E Herzel, J Kuint, G Chodick, ... Nature communications 13 (1), 1237, 2022 | 61 | 2022 |
| SARS-CoV-2 naturally acquired immunity vs. vaccine-induced immunity, reinfections versus breakthrough infections: a retrospective cohort study S Gazit, R Shlezinger, G Perez, R Lotan, A Peretz, A Ben-Tov, E Herzel, ... Clinical Infectious Diseases, 2022 | 43 | 2022 |
| Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study N Fallach, Y Segal, J Agassy, G Perez, A Peretz, G Chodick, S Gazit, ... PLoS One 17 (7), e0270893, 2022 | 42 | 2022 |
